Literature DB >> 29700689

Imaging inflammation in atherosclerotic plaques: Just make it easy!

Fabien Hyafil1, Jonathan Vigne2.   

Abstract

The presence of inflammatory cells is a hallmark of unstable atherosclerotic plaques. Several imaging approaches have been developed for the noninvasive detection of inflammatory activities in atherosclerotic plaques. Positron emission tomography (PET) imaging with the injection of 18F-fluorodeoxyglucose (FDG) is currently the most widely used imaging technique to evaluate the density of activated macrophages in atherosclerotic plaques. Nevertheless, FDG-PET imaging has logistical and technical constraints that represent an important obstacle to the wider use of this approach for the evaluation of patients with atherosclerosis. In a similar way as in the oncological field, the balance between the benefits and costs of new drugs need to be improved in patients with cardiovascular diseases. PET imaging of plaque inflammation might represent a very useful tool to identify patients who could benefit the most from anti-inflammatory treatments and to exclude patients with other causes of inflammation who are the most likely to develop severe side effects under these drugs. The availability of radiotracers targeting more specifically inflammation in atherosclerotic plaques would greatly facilitate the logistic organization of this imaging and help to expand the use of PET for the evaluation of atherosclerotic patients.

Entities:  

Keywords:  Atherosclerosis; PET; inflammation; molecular imaging; molecular imaging agents; vascular imaging

Year:  2018        PMID: 29700689     DOI: 10.1007/s12350-018-1289-5

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  18 in total

1.  Imaging intraplaque inflammation in carotid atherosclerosis with 11C-PK11195 positron emission tomography/computed tomography.

Authors:  Oliver Gaemperli; Joseph Shalhoub; David R J Owen; Frederic Lamare; Saga Johansson; Naghmeh Fouladi; Alun H Davies; Ornella E Rimoldi; Paolo G Camici
Journal:  Eur Heart J       Date:  2011-09-19       Impact factor: 29.983

2.  Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.

Authors:  P M Ridker; N Rifai; M A Pfeffer; F M Sacks; L A Moye; S Goldman; G C Flaker; E Braunwald
Journal:  Circulation       Date:  1998-09-01       Impact factor: 29.690

3.  Folate receptor-β imaging using 99mTc-folate to explore distribution of polarized macrophage populations in human atherosclerotic plaque.

Authors:  Nynke A Jager; Johanna Westra; Reza Golestani; Gooitzen M van Dam; Philip S Low; René A Tio; Riemer H J A Slart; Hendrikus H Boersma; Marc Bijl; Clark J Zeebregts
Journal:  J Nucl Med       Date:  2014-10-30       Impact factor: 10.057

4.  N-(4-18F-fluorobenzoyl)interleukin-2 for PET of human-activated T lymphocytes.

Authors:  Valentina Di Gialleonardo; Alberto Signore; Andor W J M Glaudemans; Rudi A J O Dierckx; Erik F J De Vries
Journal:  J Nucl Med       Date:  2012-04-12       Impact factor: 10.057

5.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.

Authors:  P M Ridker; M Cushman; M J Stampfer; R P Tracy; C H Hennekens
Journal:  N Engl J Med       Date:  1997-04-03       Impact factor: 91.245

6.  Quantification of inflammation within rabbit atherosclerotic plaques using the macrophage-specific CT contrast agent N1177: a comparison with 18F-FDG PET/CT and histology.

Authors:  Fabien Hyafil; Jean-Christophe Cornily; James H F Rudd; Josef Machac; Laurent J Feldman; Zahi A Fayad
Journal:  J Nucl Med       Date:  2009-05-14       Impact factor: 10.057

Review 7.  From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I.

Authors:  Morteza Naghavi; Peter Libby; Erling Falk; S Ward Casscells; Silvio Litovsky; John Rumberger; Juan Jose Badimon; Christodoulos Stefanadis; Pedro Moreno; Gerard Pasterkamp; Zahi Fayad; Peter H Stone; Sergio Waxman; Paolo Raggi; Mohammad Madjid; Alireza Zarrabi; Allen Burke; Chun Yuan; Peter J Fitzgerald; David S Siscovick; Chris L de Korte; Masanori Aikawa; K E Juhani Airaksinen; Gerd Assmann; Christoph R Becker; James H Chesebro; Andrew Farb; Zorina S Galis; Chris Jackson; Ik-Kyung Jang; Wolfgang Koenig; Robert A Lodder; Keith March; Jasenka Demirovic; Mohamad Navab; Silvia G Priori; Mark D Rekhter; Raymond Bahr; Scott M Grundy; Roxana Mehran; Antonio Colombo; Eric Boerwinkle; Christie Ballantyne; William Insull; Robert S Schwartz; Robert Vogel; Patrick W Serruys; Goran K Hansson; David P Faxon; Sanjay Kaul; Helmut Drexler; Philip Greenland; James E Muller; Renu Virmani; Paul M Ridker; Douglas P Zipes; Prediman K Shah; James T Willerson
Journal:  Circulation       Date:  2003-10-07       Impact factor: 29.690

8.  Detection of Atherosclerotic Inflammation by 68Ga-DOTATATE PET Compared to [18F]FDG PET Imaging.

Authors:  Jason M Tarkin; Francis R Joshi; Nicholas R Evans; Mohammed M Chowdhury; Nichola L Figg; Aarti V Shah; Lakshi T Starks; Abel Martin-Garrido; Roido Manavaki; Emma Yu; Rhoda E Kuc; Luigi Grassi; Roman Kreuzhuber; Myrto A Kostadima; Mattia Frontini; Peter J Kirkpatrick; Patrick A Coughlin; Deepa Gopalan; Tim D Fryer; John R Buscombe; Ashley M Groves; Willem H Ouwehand; Martin R Bennett; Elizabeth A Warburton; Anthony P Davenport; James H F Rudd
Journal:  J Am Coll Cardiol       Date:  2017-04-11       Impact factor: 24.094

9.  Targeting mannose receptor expression on macrophages in atherosclerotic plaques of apolipoprotein E-knockout mice using 111In-tilmanocept.

Authors:  Zohreh Varasteh; Fabien Hyafil; Nadège Anizan; Devy Diallo; Rachida Aid-Launais; Sarajo Mohanta; Yuanfang Li; Miriam Braeuer; Katja Steiger; Jonathan Vigne; Zhengtao Qin; Stephan G Nekolla; Jean-Etienne Fabre; Yvonne Döring; Dominique Le Guludec; Andreas Habenicht; David R Vera; Markus Schwaiger
Journal:  EJNMMI Res       Date:  2017-05-03       Impact factor: 3.138

10.  Imaging of atherosclerosis, targeting LFA-1 on inflammatory cells with 111In-DANBIRT.

Authors:  E J Meester; B J Krenning; R H de Blois; J P Norenberg; M de Jong; M R Bernsen; K Van der Heiden
Journal:  J Nucl Cardiol       Date:  2018-03-13       Impact factor: 5.952

View more
  3 in total

1.  IRF-1 contributes to the pathological phenotype of VSMCs during atherogenesis by increasing CCL19 transcription.

Authors:  Yongbin Shen; Zhanfeng Sun; Shuran Mao; Yingnan Zhang; Weiliang Jiang; Haitao Wang
Journal:  Aging (Albany NY)       Date:  2020-11-16       Impact factor: 5.682

2.  Case Report: Arterial Wall Inflammation in Atherosclerotic Cardiovascular Disease is Reduced by Olamkicept (sgp130Fc).

Authors:  Dominik M Schulte; Georg H Waetzig; Harald Schuett; Marlies Marx; Berenice Schulte; Christoph Garbers; Juliane Lokau; Ann-Kathrin Vlacil; Juliane Schulz; Anna K Seoudy; Bernhard Schieffer; Philip Rosenstiel; Marcus Seeger; Matthias Laudes; Stefan Rose-John; Ulf Lützen; Karsten Grote; Stefan Schreiber
Journal:  Front Pharmacol       Date:  2022-06-09       Impact factor: 5.988

3.  Molecular Imaging of a New Multimodal Microbubble for Adhesion Molecule Targeting.

Authors:  Mona Ahmed; Björn Gustafsson; Silvia Aldi; Philip Dusart; Gabriella Egri; Lynn M Butler; Dianna Bone; Lars Dähne; Ulf Hedin; Kenneth Caidahl
Journal:  Cell Mol Bioeng       Date:  2018-11-28       Impact factor: 2.321

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.